RxDoctor Payments Data
★ My doctorsLook up a doctor →

Vivek Veerapaneni, MD

Nephrology · Las Vegas, NVNPI 1225215684

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,457 of the $5,487 with a category attached, or 81.2%. It is spread thinly across 23 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations.

$5,487in general payments, 2019–2025

Across 97 payments — averaging $56.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bard Peripheral Vascular, Inc.$693
  • Travere Therapeutics, Inc.$680
  • Bayer$560
  • GSK$528
  • Amgen$503
  • Calliditas Therapeutics US Inc.$411
  • plus $2K from 17 others
$9,030in research payments, 2019–2025

Across 2 payments — averaging $4515.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merit Medical Systems Inc$9K

What the payments were for

  • Consulting fees$4508%
  • Travel & lodging$58011%
  • Food & beverage$4,45781%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bard Peripheral Vascular, Inc.6$693
Travere Therapeutics, Inc.15$680
Bayer18$560
GSK7$528
Amgen10$503
Calliditas Therapeutics US Inc.6$411
AstraZeneca(2 entities)8$307
Novo Nordisk3$265
EMD Serono, Inc.2$253
Aurinia Pharma U.S., Inc.2$250
Mallinckrodt Hospital Products Inc.2$161
Kerecis Limited1$159
Boehringer Ingelheim3$150
Baxter Healthcare1$124
Nxstage Medical, Inc.1$98
Sanofi-aventis U.S. LLC1$90
Mozarc Medical US LLC2$86
Akebia Therapeutics Inc2$37
Ardelyx, Inc.2$34
Vifor Pharma, Inc.2$31
Argenx US, Inc.1$29
ANI Pharmaceuticals, Inc.1$25
Medtronic1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,487 in reported general payments places this provider in the 80th percentile of 125 nephrology providers in Nevada.

See all nephrology providers in Nevada →

Medicare billing

Part B allowed, 2024
$214,996
Medicare patients
523
Services billed
1,668

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sevelamer Carbonate12$2,427

Paid to pharmacies, not to this prescriber.

Other nephrology in Las Vegas

See the full list for Nevada →

Where these figures come from

Is this you, or does something look wrong? →